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Tanja Opriessnig1,2* , Ashley A. Mattei1, Anbu K. Karuppannan3 and Patrick G. Halbur2Abstract
Deliberate infection of humans with smallpox, also known as variolation, was a common practice in Asia and dates
back to the fifteenth century. The world’s first human vaccination was administered in 1796 by Edward Jenner, a
British physician. One of the first pig vaccines, which targeted the bacterium Erysipelothrix rhusiopathiae, was
introduced in 1883 in France by Louis Pasteur. Since then vaccination has become an essential part of pig
production, and viral vaccines in particular are essential tools for pig producers and veterinarians to manage pig
herd health. Traditionally, viral vaccines for pigs are either based on attenuated-live virus strains or inactivated viral
antigens. With the advent of genomic sequencing and molecular engineering, novel vaccine strategies and tools,
including subunit and nucleic acid vaccines, became available and are being increasingly used in pigs. This review
aims to summarize recent trends and technologies available for the production and use of vaccines targeting pig
viruses.
Keywords: Vaccines, Review, Viruses, pigsBackground
A vaccine is a substance used to provide immunity
against a disease, by stimulating the production of anti-
bodies, developing cellular immunity or both. It can be
prepared from the causative agent of a disease, its prod-
ucts, or a synthetic substitute treated to act as an antigen
without inducing the disease [1]. The origins of vaccinol-
ogy, known as “variolation”, date at least back to the
fifteenth century in China [2]. Variolation is a type of
inoculation through which people were exposed to
smallpox (variola) by blowing dried smallpox scabs into
their nose (https://www.nlm.nih.gov/exhibition/small-
pox/sp_variolation.html), and was introduced to Britain
and New England early in the eighteenth century [3].
The term “vaccine” was created by Edward Jenner, an
English physician working on smallpox in humans, it is© The Author(s). 2020 Open Access This artic
which permits use, sharing, adaptation, distrib
appropriate credit to the original author(s) and
changes were made. The images or other thir
licence, unless indicated otherwise in a credit
licence and your intended use is not permitte
permission directly from the copyright holder
The Creative Commons Public Domain Dedica
data made available in this article, unless othe
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Full list of author information is available at the end of the articlethought to be derived from the Latin word “vacca” for
cow and the cowpox virus administered to humans was
designated as “vaccinia” [4]. This effort led to the first
available vaccine for humans in 1796 [4]. Almost 100
years later, Louis Pasteur used the term vaccine in 1881
for immunizations directed at other diseases besides
smallpox [5]. He also investigated mechanisms for at-
tenuation and inactivation of microbes [5]. As a result,
one of the first vaccines for pigs was introduced in
France in response to severe disease outbreaks with high
pig morbidity and mortality due to erysipelas [6]. This
pig vaccine consisted of an initial exposure to
attenuated-live bacteria derived from passaging in rab-
bits (also known as lapinization), followed by inoculation
of unaltered live virulent bacteria 12 days later [6].
Early efforts in large-scale controlled processes and
industrialization of veterinary vaccine production began
between 1930 and 1940 in Germany to produce foot and
mouth disease virus (FMDV) vaccine antigen [7]. Both
bacterial and viral vaccines commonly used the
attenuated-live or the inactivated approaches to allowle is licensed under a Creative Commons Attribution 4.0 International License,
ution and reproduction in any medium or format, as long as you give
the source, provide a link to the Creative Commons licence, and indicate if
d party material in this article are included in the article's Creative Commons
line to the material. If material is not included in the article's Creative Commons
d by statutory regulation or exceeds the permitted use, you will need to obtain
. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
tion waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
rwise stated in a credit line to the data.
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timately resulting in wider distribution. Production and
management changes, including increasing herd size and
housing, genetic improvements of the pig itself, nutri-
tional changes, generation of specific-pathogen free
herds and other changes were introduced to pig produc-
tion towards the end of the last century. These changes
also opened up avenues for easier and more rapid virus
spread, resulting in high morbidity and mortality in
some pig production systems. Hence, the need to protect
pigs from viruses via vaccination has become critical for
many pig producers. Both attenuated-live and inacti-
vated vaccine approaches are technologies from more
than a century ago, yet they have remained popular in
today’s pig production industry.
Many of the vaccines used today are far from perfect.
An ideal vaccine should produce “sterilizing immunity”
in the vaccinated individual or animal, i.e., exposure to
the pathogen should not result in any infection [8].
However, the many subtleties of the phenomenon of
evolution have given pathogens an upper hand against
vaccines for several diseases. Pathogen species are often
highly variable and commonly differentiated as sero-
types/serovars, genotypes, low/medium/high virulent
isolates, among other terms. Furthermore, they continue
to evolve in the face of vaccination. Even within a spe-
cies, pathogens vary significantly in their pathogenicity
and virulence. Pathogens also vary in their tissue of pref-
erence for replication and their mode of transmission.
Examples include simple secretion into the environment
versus very specific transmission through coitus, across
the placental barrier, or via saliva through biting. As the
timeline of all of these processes is different, this is
enumerated as the basic reproduction number (R0)
which indicates how contagious an infectious disease
is; an outbreak is expected to continue if R0 has a
value > 1 and to end if R0 is < 1 [9]. This broadly de-
pends on the period of shedding of the pathogen
from the infected animal, mode of transmission of the
infection, and herd density/contact rate between sus-
ceptible individuals [9]. In addition to pathogen-
specific factors, the host immunogenetics also play a
role in the development of immunity and resistance
to infection. Hence, developing vaccines is unique for
every infection or pathogen. In addition, a less than
perfect vaccine, which does not elicit a sterile immun-
ity, may still be useful in mitigating an infection at
the individual pig level and limit its spread to the rest
of the herd by reducing the shedding of the pathogen
and enhancing a pig’s resistance to initiation of
infection.
This review aims to provide a summary on viral vac-
cines in pigs with an outlook on new developments that
may become important in the near future.Source of virus vaccines
Commercial vaccines
In general, the virus contained in a vaccine candidate is
sourced from the overall virus population of a larger
geographic area with the purpose to protect as many
pigs as possible. The sourcing and selection process can
take months to years and is principally influenced by the
ability of the vaccine candidate to induce a response that
broadly neutralizes prevailing variants (serotypes, geno-
types, etc.) in the region where the vaccine is to be used.
This is followed by government-stipulated safety and ef-
ficacy trials in experimentally-infected pigs and in field
trials. If all set requirements are fulfilled, eventually the
vaccine is commercialized, licensed for a certain area
and then becomes available for use. Some vaccine vi-
ruses may also be used on a global basis if they match
and protect against most virus variants present and if
regulatory compliance in each of the countries has been
fulfilled. For example, the source of one of the major at-
tenuated porcine reproductive and respiratory syndrome
virus (PRRSV) vaccines, Ingelvac PRRS® MLV, Boehrin-
ger Ingelheim Vetmedica, was the US field strain
VR2332 isolated in Minnesota, USA in 1992 [10]. This
vaccine first became available in 1994 and continues to
be widely used on a global basis [11]. Most of the cur-
rently used inactivated porcine parvovirus (PPV) vac-
cines are based on strain NADL2 [12] which was first
described in 1976 [13]. A novel subunit PPV vaccine
(ReproCyc® ParvoFLEX, Boehringer Ingelheim) came on
the European market in 2018 and is based on strain 27a,
first isolated in 2001 [14].Autogenous vaccines
For some viruses, especially those that mutate frequently
(i.e. RNA viruses) and where several diverse genotypes
exist, commercial vaccines, which incorporate a “repre-
sentative vaccine candidate”, may not always provide
sufficient protection. In this case, autogenous vaccines
can be used. Autogenous vaccines utilize local farm-
specific strains that are isolated and propagated in spe-
cialized labs before a final vaccine preparation is sent
back to the farm of origin where it is used to protect the
pig herd. Safety and efficacy trials are not typically re-
quired or completed. This approach is commonly used
for viruses such as PRRSV, where there are many differ-
ent virus types and vaccine protection is considered to
be correlated to its closeness to the farm-specific virus.
Due to biosecurity risks, autogenous vaccines are only
allowed to be used on the farm or within the production
system from where the virus originated. In general,
guidelines on production and use of autogenous vaccines
vary from country to country and commonly there are
certified autogenous vaccine production sites available.
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This refers to vaccines that to the authors’ knowledge
are not available yet but are designed for pigs with a spe-
cific genetic background. For example, different pig
breeds such as Pietrain, Large White, Landrace or
others, and even lineages within a breed, may vary in
their response to a given vaccine and investigating this
may offer new clues on decreased vaccine efficacy on
certain farms. Although there is not an exhaustive know-
ledge base built on the immunogenetics of swine, it is
known that variations in immune response occur due to
swine major histocompatibility complex (MHC) poly-
morphisms [15]. However, differences in MHC genes are
just one aspect of immunogenetic variations and more
remains to be unravelled. It is already known that in
humans females have a better immune response com-
pared to males [16, 17]. It is presently unknown if this
observation holds true in pigs or other animal species.
The accumulation of knowledge in the various disci-
plines of vaccinology may phase out the era of “one size
fits all” vaccines in favour of products individually tai-
lored for a specific population of pigs.
Composition
There are several types of vaccines commonly used in
pigs. Broadly, these can be categorized into whole patho-
gen, subunit and nucleic acid-based vaccines (Table 1).
Moreover, vaccines can also be monovalent (protection
against a single virus strain) or multivalent/polyvalent
(protection against two or more strains of the same virus
or two or more different viruses). Vectored vaccines in
particular have great potential to protect against more
than one strain or virus. An excellent review has been
recently published on this topic [18].
Whole pathogen vaccines
Attenuated-live whole pathogen vaccines
Attenuated-live vaccines are typically obtained by serial
passaging viral strains either in pigs, in heterologous spe-
cies such as rabbits (lapinization), or in cell culture. TheTable 1 Types of vaccines used in pigs
Main vaccine category Subtypes
Whole pathogen • Attenuated-live
• Inactivated (killed
• Chimeric (attenu





Nucleic acid based • DNA plasmid(s)
• mRNA
aVirus-like particles (VLPs) are often producedvirus stock is regularly checked during the serial passage
until inoculated pigs no longer display clinical signs.
This attenuated virus vaccine stock is then used for vac-
cine production. Attenuated-live vaccines, which mimic
the process of natural infection but are not pathogenic,
elicit strong immune responses that can confer life-long
immunity after only one or two doses. Especially for
RNA viruses, which include PRRSV and influenza A
virus (IAV) among other viruses, the immune response
is greatly improved if it is triggered by a live virus.
Attenuated-live vaccines are relatively easy to create for
certain viruses but also have major disadvantages, in-
cluding safety (Table 2). Attenuated-live vaccines are
commonly used for control of PRRSV [11] and are
widely available on a commercial basis (Table 3). How-
ever, as there are two main PRRSV species and many
subtypes within each species [19, 20], protection is com-
monly only efficient with homologous vaccine virus
strains and requires genomic sequencing of the farm
specific PRRSV strain first [21]. Regardless, genomic
homology of the PRRSV open reading frame (ORF) 5 se-
quence of attenuated vaccines is not always predictive of
their efficacy [22]. Safety issues with PRRSV attenuated
vaccines are not uncommon [23, 24]. A recently docu-
mented incident demonstrates the recombination of two
species of PRRSV vaccine strains associated with severe
disease outbreaks in Danish pigs in 2020 [25]. A bivalent
attenuated-live IAV vaccine entered the US market in
2017 and is licensed for piglets as young as 1 day old. In
experimental trials this vaccine showed significant re-
duction of nasal IAV shedding when pigs were chal-
lenged 12 weeks after vaccination [26]. Recently,
evidence of re-assortment of the live attenuated IAV
vaccine virus with endemic field strains circulating in
the US was detected [27]. The report raises concerns
over the safety of this particular vaccine.
A novel approach to rapidly attenuate viruses includes
computer-aided codon pair deoptimization, also known
as synthetic attenuated virus engineering (SAVE) ap-
proach [28]. For pigs, this approach has been)
ated-live or inactivated)
ellular organisms without a distinct nucleus)
i, Bacillus subtilis
llular or multicellular organisms with an enveloped nucleus)
lian cells, baculovirus expression in insect cells, plants, transgenic animals
virus vectors (replicating or replication deficient)
Table 2 Simplified advantages and disadvantages of traditionally used, widely available viral attenuated-live and inactivated vaccine
types in pigs
Attenuated-live Inactivated
Administration routes (IM), oral, intranasal, intradermal IM, intradermal
Adjuvant None Required
Number of doses One dose Often two doses
Humoral immunity IgG IgG
Secretory immunity IgA –
Cellular immunity Yes –
Long-term immunity Yes –




Transmission among pigs Yes No
Production cost Low (involves only culture, bottling and
lyophilization or freezing)
High (requires a high antigen content, addition of
adjuvant and other excipients)
Time until a vaccine is available Months to years Months
aNeeds to be stored at −80 °C or lyophilized. Cannot be stored once opened
bStorage at room temperature or at + 4 °C (never frozen) for longer periods; can be used for some time after opening a bottle. Phase separation of the aqueous
and oil phases in the vaccine formulation may be observed in some vaccines, which can be corrected by vigorous shaking of the vaccine container
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codon pair deoptimization of the gene encoding the
major envelope GP5 protein resulted in attenuation of
the virus [29]. In a subsequent challenge study, the pre-
viously constructed SAVE PRRSV vaccine virus was ef-
fective in protecting pigs against homologous virus
challenge [30]. These results are promising as overall
production of a deoptimized vaccine virus may only take
weeks to month. Additionally, in contrast to traditional
attenuated viruses, which have an inherent risk of rever-
sion to virulence, the deoptimization during the SAVE
approach induces several minor changes which make a
reversion to virulence unlikely [29].
Inactivated whole pathogen vaccines
These vaccines consist of entire pathogens that have
been inactivated or killed so that they cannot cause dis-
ease in vaccinated pigs. Vaccines in this category are
produced by inactivating the pathogen with chemical
(commonly formaldehyde; beta-propiolactone or binary
ethylenimine) or physical (thermal such as heat or radi-
ation) treatment. Inactivated vaccines emerged for use in
pigs shortly after World War II and several adaptions
and improvements have been introduced over time. Ad-
vantages and disadvantages of inactivated vaccines are
listed in Table 2 and compared with attenuated-live vac-
cines. A pig virus that is commonly controlled by use of
inactivated vaccines is IAV [31]. This may be in part due
to the perceived risk of live vaccines giving way to reas-
sortant viruses or reversion to virulence [27]. Any new
IAV variant (recombination, re-assortment) could be
detrimental to pigs but also other species includinghumans due to its cross-species tropism. A recent ex-
ample of recombination of IAV portions from different
species resulted in the pH1N1 pandemic during 2009
[32].
Chimeric whole pathogen vaccines
Genetic engineering techniques have enabled the cre-
ation of chimeric viruses, which contain genetic infor-
mation from and display biological properties of two
different parent viruses. Such vaccines represent a whole
fused pathogen and often the fusion of two virus por-
tions results in natural attenuation and reduction of rep-
lication. These attenuated-live chimeric viruses can be
further inactivated for additional safety. Alternatively,
chimeric viruses may not be viable and hence are con-
sidered inactive. An example is a chimeric virus used to
vaccinate pigs against porcine circovirus type 2 (PCV2).
While PCV2, discovered in 1998, is pathogenic, porcine
circovirus type 1 (PCV1), discovered prior to PCV2 in
the 1970s, is non-pathogenic [33]. A chimeric infectious
clone was created in 2002 by fusing PCV1 ORF1 (re-
sponsible for viral replication) with PCV2 ORF2 (en-
codes the capsid protein against which antibodies are
generated) [34]. The resulting PCV1–2 chimeric virus
was shown to replicate in pigs at a low level without
causing disease or lesions; however, it generated a strong
humoral immune response to PCV2 [34]. In subsequent
studies the attenuated PCV1–2 was found safe for use in
pigs and able to protect growing pigs from the conse-
quences of PCV2 challenge [35, 36] and also pregnant
sows [37]. The final vaccine preparation that entered the
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on PCV2, several genotypes were identified of which
PCV2a, PCV2b and PCV2d appear to be of greatest im-
portance [38]. This vaccine has now been updated to
contain two different PCV1–2 types, one based on ORF2
of PCV2a and one based on ORF2 of PCV2b (https://
www.zoetisus.com/news-and-media/zoetis-introduces-u.s.
-pork-industry_s-first-vaccine-with-two-pcv2-genotypes.
aspx). A slightly different approach in addition to the
chimeric PCV1–2 clone was introduced in 2016 [39]. In
brief, the capsid gene (ORF2) of available PCV2 geno-
types was subjected to deoxyribonucleic acid (DNA)
shuffling resulting in a capsid gene that contained
portions of different PCV2 genotypes. This so gener-
ated capsid sequence was inserted in the PCV1 back-
bone as described above. This chimeric virus induced
protective immunity against PCV2b and PCV2d under
experimental conditions [39]. A chimeric full-length
PRRSV clone was generated by inserting shuffled
structural genes (ORFs 3–6) from six heterologous
PRRSV strains into the backbone of PRRSV strain
VR2385. This chimeric PRRSV virus conferred an en-
hanced cross-protection in vaccinated pigs when chal-
lenged with the heterologous virus strain NADC20 or the
contemporary heterologous strain RFLP 1-7-4 [40].
Subunit vaccines
This type of vaccine contains viral components, also known
as antigens, capable of stimulating the immune system. An-
tigens are commonly expressed using prokaryotes (Escheri-
chia coli, Bacillus subtilis), eukaryotes (yeast, mammalian
cells, baculovirus in insect cells, plants, and animals), or
mammalian viruses including replicating or replication defi-
cient variants. In general, the subunit vaccine design can
make vaccines safer as well as production and quality con-
trol between batches easier [41] compared to live attenu-
ated viruses or inactivated viruses. However, incorporation
of adjuvants to elicit a strong protective immune response
is often essential. Subunit vaccines can be administered as
crude material that includes the expression vector, some-
times with adjuvant properties, or as purified proteins.
Crude material for instance was used in the early days of
PCV2 vaccination and an ELISA detecting baculovirus anti-
bodies was offered at certain diagnostic laboratories includ-
ing at Iowa State University to confirm successful
vaccination of pigs (TO personal observation). Another ex-
ample is the BAYOVAC CSF E2 vaccine for classical swine
fever (Bayer AG, Germany), which in 1998 contained the
E2 protein of the virus along with chemically (BEI) inacti-
vated baculovirus (https://www.ema.europa.eu/en/docu-
ments/procedural-steps/advasure-epar-procedural-steps-
taken-authorisation_en.pdf). It is possible that the in-
cluded antigens alone are not sufficient to induce adequate
long-term immunity; however, including only the essentialantigens in a vaccine can minimize any potential side
effects.
Prokaryotic vectors (i.e. primarily unicellular organisms
without a distinct nucleus)
The E. coli vector has a fast growth rate, an overall low
cost and high protein yield. Disadvantages include the
lack of eukaryotic co- and post-translational modifica-
tions, proteins may often be insoluble, and the codon
usage is different from eukaryotes. Specifically engi-
neered bacteria, able to induce specific post-translational
modifications, are now occasionally used for a unique
protein of interest but the process is difficult [42]. Sev-
eral experimental PCV2 vaccines have been described
using the E. coli vector [43–45]. In addition, an E. coli
-expressed PRRSV chimeric protein induced a specific
immunoglobulin G response in vaccinated pigs [46]. The
B. subtilis vector has been experimentally used in pigs as
an oral vaccine expressing the PCV2 capsid protein [47].
A mucosal response was seen when piglets were vacci-
nated orally with the porcine epidemic diarrhea virus
(PEDV) COE antigen, which is a collagenase-digested
fragment of the spike protein, expressed by B. subtilis
[48]. Advantages of B. subtilis include that this vector
can be used for mucosal immunization via a non-
invasive needle-free route, as it is considered a
temperature resistant immunogen [49].
Eukaryotic vectors (i.e. unicellular or multicellular
organisms with an enveloped nucleus)
Yeast Advantages of yeast vectors are a fast growth rate,
a high protein yield, low production cost, and good pro-
tein folding. Despite these advantages this vector is not
commonly used in pig vaccinology. Commonly used
yeast vectors include Saccharomyces cerevisiae,
Schizosaccharomyces pombe, Saccharomyces boulardii,
Hansenula polymorpha, Pichia pastoris, Candida
boldmu, Kluyveromyces lacti, Yarrowia lipolytica, and
others. Yeast vectors in pigs have been suggested for
vaccines against PEDV. Specially, under experimental
conditions, a whole yeast vaccine expressing the PEDV
S1 protein induced a high PEDV IgA response in pigs
when administered orally [50]. Another example of
this expression platform in pigs is the production of
the ectodomain of the immunologically relevant
hemagglutinin-neuraminidase glycoprotein of porcine
rubulavirus, which induced neutralizing antibodies in
mice [51].
Mammalian cells Mammalian cells are naturally fitted
for the production and secretion of complex molecules
with precise glycosylation. However, this system has not
yet been adopted for common use in pig vaccine
Opriessnig et al. Porcine Health Management             (2021) 7:1 Page 7 of 16production. In general, the speed of production is low,
the cost is high, and there is also the potential for en-
dogenous virus contamination [52]. However, clear ad-
vantages of this expression system include that there is a
medium-to-high scale-up capacity, the system overall
can reach high and robust productivity of secreted pro-
teins in serum-free medium, and mammalian cells have
the ability to perform complex post-transcriptional mod-
ifications. The two most common cell lines employed
are the Chinese hamster ovary (CHO) and the human
embryonic kidney 293 (HEK-293) cell lines [52]. A re-
cent study compared the ability of yeast, insect and
mammalian cells to produce a PEDV S1 vaccine protein
[53]. Of the three eukaryotic expression systems tested,
HEK-293 T cells gave the highest yield of protein (N-gly-
cosylated). Vaccination of a sow resulted in induction of
S1-specific IgG and IgA that were passively transferred
to the suckling piglets. High virus neutralization titres
were measured in the serum of the vaccinated sow and
its piglets [53]. In another example, HEK-293 cells were
used to express the classical swine fever virus (CSFV) E2
glycoprotein [54]. Similarly, CSFV E2 proteins have also
been successfully produced in CHO cells [55].
Baculovirus vector in insect cells This system results
in good protein folding; however, the protein yield is
lower than with other methods and hence raises produc-
tion costs. The baculovirus vector has been used for nu-
merous experimental vaccines and is now used in the
production of several commercial pig vaccines (Table 3).
Among many others, additional examples where the
baculovirus vector has been used successfully under ex-
perimental conditions include pseudorabies virus (PRV)
(glycoprotein D) [56], hepatitis E virus (HEV) [57] or
CSFV [58].
Plants Examples of plant-expressed vaccines include
CSFV, for which the structural glycoprotein E2 is com-
monly used [59, 60]. For example, when using the Ni-
cotiana benthamiana plant expression system, purified
recombinant E2 protein generated high titers of neutral-
izing antibodies in pigs and mice when injected intra-
muscularly [60]. Furthermore, transplastomic tobacco
was used to produce a subunit vaccine candidate against
PEDV [61]. Interestingly, the plant biomass matrix was
shown to delay degradation of the chloroplast-produced
rFaeGntd/dsc in gastrointestinal conditions, suggesting
its possible use as an oral vaccination strategy [61]. Simi-
larly, embryogenic cells of banana plants have been
transformed with the ORF5 gene of PRRSV using
Agrobacterium-mediated transformation [62]. Pigs were
orally immunized with recombinant GP5 protein by
feeding them with transgenic banana leaves three times
at 2-week intervals and were then challenged withPRRSV at 7 weeks post initial immunization. These or-
ally vaccinated pigs had increased anti-PRRSV IgG and
IgA antibodies, lower viremia and tissue viral loads com-
pared to non-vaccinated pigs [62]. There have also been
reports of PRRSV expression in tobacco [63] and potato
plants [64]. Advantages of the plant expression system
versus the baculovirus/insect cell system are the poten-
tial scalability as well as the lower cost of production
and immunogenicity [59].
Transgenic animals Producing recombinant proteins in
animal bioreactors could present an excellent tool for
vaccine production [65]. For instance, a certain vaccine
protein could be excreted in the milk of dairy cattle via
generation of transgenic animals. However, negative as-
pects include the long time between the production of
such a transgenic cow and its first lactation cycle, which
additionally is intermittent in nature. The use of trans-
genic chicken eggs for large scale recombinant protein
production appears to be a better avenue; however, so
far this system has mainly been used for the production
of specific antibodies by vaccinating the hen to provide
passively acquired immunity to other species [65]. In
pigs, a specific example is their passive protection from
FMDV infection and transmission by immunization with
Llama single-domain antibody fragments [66].
Virus-like particles VLPs are self-assembling, non-
replicating and non-pathogenic, highly organized, supra-
molecular multi-protein nanoparticles (ranging from 20
to 100 nm) that can be formed from the minimal spon-
taneous self-assembly of one or more viral structural
capsid proteins, giving empty viral particles devoid of
genetic material [67]. Hence, they prompt an immune
response similar to that elicited by the natural virus, but
VLPs are non-infectious because they do not contain the
genetic material the virus needs to replicate inside cells.
VLP assembly may also take place inside the host cell
through self-assembly. VLPs are usually produced in
bacteria, yeast, or the baculovirus/insect cell system [68].
Several baculovirus-expressed commercial PCV2 vac-
cines have been shown to contain a certain percentage
of VLPs [69]. Recently, an efficient application of a
baculovirus-silkworm larvae expression system for PCV2
VLP production has been described [70]. Efficient pro-
duction of PCV2 VLPs was reported using the non-
conventional yeast species Kluyveromyces marxianus
[71]. Foot-and-mouth disease virus (FMDV) VLPs have
been suggested as a non-replicating vaccine candidate
[72]. Specifically, VLPs composed entirely of FMDV cap-
sid proteins were simultaneously produced as small
ubiquitin-like modifier (SUMO) fusion proteins by an
improved SUMO fusion protein system in E. coli. Intra-
muscular immunization of pigs with the FMDV VLPs
Opriessnig et al. Porcine Health Management             (2021) 7:1 Page 8 of 16induced a protective immune response against homolo-
gous FMDV challenge [72]. Finally, several studies re-
ported the generation of E. coli-derived PCV2 VLPs [73,
74]. Of note, self-assembling proteins could coincide
with the actual antigen for vaccination or could be car-
riers for other antigens expressed as fusion proteins. An
example of the latter is the use of Hepatitis B virus core
antigen as a carrier protein for the conserved protective
epitopes of PRRSV [75]. This hybrid VLP system offers
low cost production and is safe [75].
Live mammalian viral vectors
Replicating mammalian viruses PRRSV has been pro-
posed as a live viral vector by using an attenuated strain
(DS722) to express protective antigens from IAV and
PCV2 [76]. A vaccination and challenge study in 48 pigs
revealed that the DS722-SIV-PCV2-vaccinated pigs had
significantly reduced lung lesions and viral RNA loads
when challenged with PRRSV. Upon challenge with
PCV2, the vaccinated pigs had partially reduced lymph-
oid lesions and viral DNA loads, and when challenged
with IAV the vaccinated pigs had significantly reduced
acute respiratory sign scores [76].
Replication-deficient viruses These viral vectors are
deficient of viral functions essential for replication and
assembly of progeny virus particles [77]. These viruses
are propagated in cell lines which complement the miss-
ing viral gene products; hence gene expression takes
place in infected cells, but no virus progeny is produced.
Examples of replication deficient viruses include pox-
virus, adenovirus and alphavirus species. The modified
vaccinia Ankara (MVA) strain is an attenuated vaccine
based on poxvirus [78]. A subset of African swine fever
virus (ASFV) antigens were purified from HEK cells and
produced in MVA viral vectors and evaluated in pigs
using a prime-boost concept [79]. This resulted in in-
duction of ASFV specific antibody and T-cell responses
demonstrating the feasibility of generating a safe and im-
munogenic vaccine against this devastating pig disease
[79]. Adenovirus vectors have been experimentally used
in pigs to protect them against PRRSV [80] or PEDV in
the form of a mucosal vaccine [81]. The adenovirus plat-
form was also recently used to develop PRRSV species 2
subunit vaccines by expressing swine leukocyte antigen
(SLA) class I and class II allele-specific antigens [82].
Specifically, two PRRSV poly-T-cell epitope peptides
each specific to SLA I or SLA II were used. However, in
the pig challenge study these vaccines provided little im-
provement over non-vaccinated pigs highlighting the
challenges in developing effective PRRSV subunit vac-
cines [82]. Alphaviruses have a broad host cell range, a
tropism for dendritic and monocytic cells and hence canstimulate innate immune responses [77]. In addition, in
most hosts including pigs there is no pre-existing im-
munity. Alphavirus vectors resemble yet another single
stranded replicating RNA vector and demonstrate a high
level of transient heterologous gene expression in-vivo
and in-vitro [83]. The most commonly used encapsu-
lated alphaviruses include Semliki Forest virus, Sindbis
virus and Venezuelan equine encephalitis virus [83]. The
last one has been licensed in the US as a vector for au-
togenous vaccine production (SEQUIVITY® product line;
Merck, USA) and many such vaccines are now being
used in the field. The alphavirus platform has previously
been successfully employed to protect pigs from PCV2d
challenge under experimental conditions [84]. The
alphavirus vector was also used for cluster IV H3N2 IAV
vaccine production [85].
Nucleic acid based vaccines
DNA plasmid vaccines
These typically comprise a small circular piece of epi-
somal DNA derived from prokaryotes, called a plasmid,
that is used as a vector to carry a gene(s) encoding pro-
teins from the pathogen of interest [86]. This is injected
directly into the muscle of the recipient. The muscle
cells take up the DNA, and the encoded protein antigen
is expressed in the cells, leading to both humoral and
cell-mediated immune responses. Local dendritic cells
play an important role in the development of antigenic
responses to DNA vaccines. As only a single microbial
gene or DNA encoding a set of antigenic peptides is
used, it is safe and does not carry any risk of active in-
fection [86]. The manufacturing process for DNA plas-
mid vaccines is well-established, allowing experimental
vaccines to be quickly developed to address emerging or
re-emerging infectious diseases. DNA plasmid vaccines
have been used under experimental conditions for IAV
protection and resulted in improved cellular immunity
compared to traditional inactivated vaccines [87]. Re-
cently, a DNA vaccine using a mosaic vaccine approach
has been described [88]. Mosaic vaccines are prepared
for viruses that have many different strains with limited
cross-protection. A mosaic vaccine combines pieces of
different strains with the goal to evoke a broad immune
response. A PRRSV DNA vaccine was constructed with
ORF5 PRRSV mosaic sequences, complexed to cationic
liposomes, and administered to pigs using intradermal
and intramuscular routes. This vaccine has been found
to induce cellular immune responses against several
PRRSV species 2 strains. In a subsequent challenge
study, the vaccine was found to induce broad protection
against heterologous PRRSV strains when administered
twice to pigs [88]. In addition, a DNA vaccine based on
conserved haemagglutinin (HA) peptides fused with fla-
gellin, administered with a needle-free device, induced a
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vaccinated pigs [89]. Maternally derived antibodies did
not interfere with vaccination and there was a markedly
increased mucosal IgA response in vaccinated pigs com-
pared to non-vaccinated pigs [89].
mRNA vaccines
Vaccines based on messenger RNA (mRNA), an inter-
mediary between DNA and protein, are also being devel-
oped. Recent technological advances have largely
overcome issues with the instability of mRNA and the
difficulty of delivering it into cells, and some mRNA vac-
cines have demonstrated encouraging early results.
mRNA-based vaccines have important advantages over
other vaccine approaches, including outstanding efficacy,
safety, and the potential for rapid, inexpensive, and scal-
able production [90]. A rabies vaccine for pigs has been
reported as an example of this vaccine platform [91]. In
brief, an optimized non-replicating rabies virus glycopro-
tein encoding mRNA was used to induce potent neutral-
izing antibodies in domestic pigs. Virus neutralization
titers which correlated with protection in adult and new-
born pigs, were successfully induced, demonstrating the
feasibility of a non-replicating mRNA rabies vaccine in
pigs and highlighting the promises of mRNA vaccines
for the prevention of infectious diseases [91]. Of note,
to counter the current severe acute respiratory syn-
drome-coronavirus-2 (SARS-CoV-2) epidemic, several
mRNA vaccines for human use have recently been
licensed [92, 93].
DIVA vaccines
It is often of interest to have vaccines available that can
help differentiate infected from vaccinated animals, also
known as DIVA or marker vaccines. DIVA vaccines in-
duce an immune response which is different from that
induced by natural infection. Two types of markers can
be used: Negative markers (the vaccine has at least oneTable 4 Overview of different vaccine administration routes. The su


















Mucosal No Not applicable Noantigenic protein less compared to the field strain) or
positive markers (an antigenic protein is inserted in the
vaccine) [94]. Overall, negative markers are preferred as
they allow for identification of pigs infected with field
virus which then can be removed [94]. The main advan-
tage of DIVA vaccines and their accompanying tests is
the possibility to distinguish between infected and vacci-
nated animals. Therefore, restrictions in place for in-
fected animals can be reduced for vaccinated animals. In
pigs, DIVA vaccines were first used for PRV also known
as Aujesky’s disease. Most were based on recombinant
deletion mutants that lack the gE envelope glycoprotein
and thymidine kinase genes [95]. Many of these deletion
mutants were detected in live-attenuated PRV vaccine
strains in the mid 1980s [95]. A competitive enzyme im-
munoassay was concurrently developed [96] and the ac-
cess to a marker vaccine and an assay to differentiate
infected from vaccinated pigs facilitated the eventual
eradication of PRV [97]. A commercial DIVA vaccine
for CSFV, a baculovirus-expressed recombinant E2-
subunit vaccine, is also available on the market [98].
Vaccine administration
There are a variety of traditional, trending, and alterna-
tive vaccine administration routes that are used to
vaccinate pigs (Table 4). In general, pig vaccine adminis-
tration should be fast and pig, friendly, with as little
stress as possible on the individual pigs and the people
administering the product. Preferably, the mode of vac-
cination should not be labour intensive. Intramuscular
injection is the most commonly used administration
route. Recently, routes such as intradermal, intranasal or
oral have at least been demonstrated to have the poten-
tial, in the future, to replace the traditional long-
standing intramuscular vaccination route. Especially for
intradermal applications, the dermis is an excellent site
for vaccine delivery and rich in dendritic cells as well as






Yes Risk of needle breakage and introduction of other
infections through needle puncture is high. In




Special devices and training may be needed initially.
Minimal Perhaps difficult in breeding animals; localized or
mucosal immunity may be a possible benefit in
vaccination against respiratory viruses.
No Attenuated virus vaccines are needed. Pigs need to
have access to the feed/water and need to be willing
to eat or drink at vaccination. Water quality and feed
ingredients may interfere.
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stars/pt_MSD1-8.pdf). DNA vaccines appear to benefit
from the intradermal route of administration [87, 89].
Several commercial health companies have started to
produce their own, individual intradermal injection de-
vices, which can be used on company-specific vaccine
bottles, and are sold to producers as package deals.
These devices either use needles or are needle-free. It
has been demonstrated that needle-free intradermal
vaccination reduces fear and pain reaction in gestat-
ing sows during vaccination [99]. As an example for
the oral administration route, a recent study using a
bread-based lyophilized C-strain of CSFV, tested on
backyard pig farms, has provided encouraging results
[100]. In an attempt to improve storage conditions
for backyard farmers by avoiding the need for freez-
ing, dog food, horse feed, pig feed, rice bran, and
plain sliced bread were used as candidates for the
vaccine base. Titres of the bread-based lyophilized
CSFV vaccine were stable at around 3.67 log10 50%
tissue culture infectious dose (TCID50) per ml for 7
months at 4 °C. Pigs that orally received bread-based
lyophilized CSFV vaccine showed seroconversion of
over 90% at 14 days post vaccination. This study is
also an example of how vaccine thermostability was
improved to allow vaccine delivery to be less
dependent on functioning cold chains [100].
The benefits of alternative routes may include induc-
tion of a strong localized/mucosal immune response,
especially at the point of virus entry (i.e. respiratory
system) [101, 102].
Adjuvants
Adjuvants, pharmacological or immunological agents
that improve the immune response of a vaccine, are
integral components of most vaccines used today in
pigs. Adjuvants are used to reduce the number of in-
dividual vaccine injections, which results in reduced
labour, animal stress, risk of injuries to the pig (needle
breaks, injuries due to catching the pig) and ultimately
reduced cost for the producer [103]. They can be
broadly divided into major groups based on their
main component: oil emulsion, particulate antigen car-
rier, cytokines, pathogen associated molecular patterns,
and saponins. Adjuvants are often specific for certain
routes of vaccination. For example, while the same
vaccine can be used orally, intranasally or intramuscu-
larly, each of these routes may require a different
route-specific adjuvant to enable optimal vaccine per-
formance. Adjuvants have become valuable assets for
commercial vaccine companies and are commonly
protected by patents. A detailed review on adjuvants
used in pigs including their mechanism of action has
been published recently [103].Nanoscale/microscale carriers for delivery of vaccines
Nanoparticle-based technology has received a lot of
attention lately. Nanocarriers, able to generate strong
protection after a single dose, are used to present a virus
vector, protein, subunit antigens or VLP to the immune
system. There are several options for nanocarriers that
can be used in nanovaccines including spores (bacterial),
proteasomes (cell membrane based), exosomes (cellular),
liposomes (lipid-based), virosomes (liposome and viral
envelope protein), super fluids (biodegradable polymer),
nanobeads (inert nanomaterial), VLPs (viral) and phages
(viral, bacteria as targets) [104]. Most induce humoral
and cellular immunity. At this point, commonly used
nanocarriers in pigs are polymeric nanoparticles includ-
ing polysaccharides, polyesters, chitosan and others.
Their production, characterization, toxicology and eco-
toxicology have been recently reviewed [105]. For in-
stance, an experimental inactivated IAV vaccine was
generated using chitosan and induced cell-mediated im-
munity in pigs vaccinated intranasally [106]. The IAV
extracellular domain of M2 (M2e) antigen was inserted
into the capsid protein of PCV2 and expressed in E. coli
to form a self-assembled chimeric VLP nanovaccine
[107]. High levels of M2e specific antibodies and PCV2
specific neutralizing antibodies could be induced in
vaccinated pigs [107]. The immunogenicity and pro-
tective efficacy of a polyanhydride nanoparticle-based
IAV vaccine, in which inactivated soluble antigen was
co-encapsulated with a toll-like receptor 9 agonist,
was tested in pigs challenged with IAV [108]. Results
indicated that high mucosal humoral and cellular im-
mune responses in pigs can be achieved [108]. Very
recently, a nanoparticle-Poly(I:C) combination en-
hanced the immune response in pigs (high levels of
virus neutralizing antibodies in bronchoalveolar lavage
fluid) when compared to an inactivated IAV vaccine
which was administered by the intranasal route and a
multivalent commercial IAV vaccine given intramus-
cularly [109]. Of note, microscopic lung lesions and
challenge virus loads were not different between vac-
cine groups [109].
Assessment of vaccine efficacy
Vaccine efficacy is the percentage reduction of disease in
a vaccinated group compared to an unvaccinated group,
under the most favorable conditions and was originally
defined in 1915 for human cholera and typhoid vaccines
[110]. Commonly, vaccine efficacy is initially tested
under experimental conditions using a defined challenge
model in naïve pigs (negative for antibodies against the
challenge virus). Parameters that may be assessed in-
clude reduction of clinical signs, macroscopic and
microscopic lesions, amount and duration of pathogen
shedding as well as impact on average daily weight gain
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duction in transmission of the virus, speed and breadth
of antibody responses to the vaccination may also be
assessed among other parameters. Once experimental
data are promising, field trials are initiated in large
groups of pigs that may or may not have been exposed
to the virus and hence may have active or passive
immunity.Novel tools available to further improve vaccine
development
The diagnosis and the characterization of pathogens
have made much progress since DNA was discovered in
1869 by Friedrich Miescher [111]. The first attempts at
sequencing DNA were performed in 1970 at Cornell
University (https://web.archive.org/web/20090304121126/
http://www.mbg.cornell.edu/faculty-staff/faculty/wu.cfm).
Furthermore, genetic engineering, the designed and
targeted manipulation of a genome, was first achieved
in 1973 by Herbert Boyer and Stanley Cohen [112].
Detection of viruses is today commonly performed in
veterinary diagnostic laboratories by polymerase chain
reaction (PCR), to demonstrate their presence and
quantify them. If further characterization of the virus
is desired, this may be followed by subsequent sequen-
cing which can often be conducted within 12–24 h
after the request has been raised. Today, PCR and se-
quencing are considered basic diagnostic tools in veterin-
ary diagnostic laboratories. In fact, at the Veterinary
Diagnostic Laboratory at Iowa State University, Ames,
USA, the number of PRRSV PCR tests for veterinary
diagnostic purposes was 5232 in 2002 as compared to
60,565 in 2009 and 200,209 in 2019 (data courtesy of
Dr. K. Harmon). Because of this rapid acceleration of
knowledge, a variety of new and useful disciplines in
vaccinology have evolved.Reverse vaccinology
The inclusion of whole genome sequencing and bio-
informatics in vaccine design, rather than relying only
on serological evidence, was first introduced in 2000
[113]. Viable vaccine candidates are identified by com-
putational methods, utilizing genomic information of
virus specific B- or T-cell epitopes, signal peptides, or
proteins with extracellular localization and are later vali-
dated by serological and immunological assays [114].
This approach allowed the identification of broadly
cross-reactive T-cell epitopes from two pig IAV H1 line-
ages which were further verified by in-vivo analysis in
infected pigs [115]. In another study, the extracellular
domains in the ORF 5 gene of PRRSV were combined to
create an engineered antigen which elicited neutralizing
antibodies in vaccinated pigs [116].Immunoinformatics
This approach allows understanding of immunological
information through bioinformatics and computational
approaches [117]. Analyses may be done at the level of
epitopes, subunit vaccines, attenuated or inactivated
vaccines. Goals of this approach are to efficiently and
effectively predict immunogenicity and to identify anti-
gens suitable for use in vaccines, characterizing MHC
haplotypes [118, 119] and preferably demonstrating and
confirming them in experimental challenge studies [87,
120]. It is expected that this approach will enable the
discovery of more suitable epitopes and will overall ac-
celerate vaccine design [121]. Pig vaccine applications to
date have included viral infections such as IAV, PCV2,
and ASFV [121]. Recently, this approach has also been
utilized to predict epitopes and proteins for porcine
rubulavirus [122].Immunogenetics
The genetic basis of the immune response is studied
using this discipline, including investigating normal im-
munological pathways and identifying variations that
may result in immune response defects. For instance,
IAV in-vitro refolding assays have been used to investi-
gate the affinity and stability of the binding of epitope
peptides to MHC class I molecules, which are key
factors in the presentation of peptides to cytotoxic T
lymphocytes [123]. Additionally, in the ongoing SARS-
CoV-2 epidemic, understanding the immunogenetic fac-
tors influencing the immune response to infection is
thought to be critical for patient management and iden-
tifying risk factors for fatal disease complications [124].
Similarly, understanding the host immunogenetic factors
is important in designing veterinary vaccines for efficient
control of viral infections.Systems vaccinology
In this interdisciplinary approach, complex interactions
among all the parts in a biological system are systemic-
ally described to ultimately predict its behavior [125]. In-
vestigations may target viral antigens, virulence factors,
viral host modulating genes, swine leucocyte antigen
(SLA) polymorphisms, and pig immunogenetics, which
directly and indirectly influence resistance to infection
and development of immune responses. One potential
application of this discipline is predicting vaccine effi-
cacy against known or unknown strains of a certain
pathogen [126]. Identification of molecular signatures,
which are induced rapidly in the host after vaccination
and correlate with the development of protective im-
mune responses, represents a strategy to prospectively
determine vaccine efficacy [126].
Opriessnig et al. Porcine Health Management             (2021) 7:1 Page 12 of 16Knowledge gaps
Although the production of vaccines against porcine
viral diseases has progressed considerably, there are still
many pig viral diseases with insufficient solutions. The
swine industry would likely prefer to have single dose
multivalent products that can be administered with min-
imal labour (i.e. via water, feed, air) and protect growing
pigs from weaning to slaughter, by providing excellent
efficacy against most variant strains that exist for a given
virus. It should also be noted that for breeding herds
and boar studs it would be desirable that products with
zero risk of endangering the breeding stock are adminis-
tered once a year (in contrast to the current need of ad-
ministration every 6 months or at every reproductive
cycle). Spray application/nebulization vaccination is
commonly used in poultry, yet this technique has yet to
be further developed for pig farms to make it effective,
practical and cost effective. Experimental trials using in-
tranasal nebulization for IAV vaccine administration
have shown promising potential [127].
Summary and discussion
The first veterinary vaccine for pigs became available
approximately 150 years ago and today there is a large
repertoire of pig vaccines available. Viral vaccines are
used on a regular basis and are considered essential in
modern pig production. With all the advances in recent
years it remains puzzling why there is still no fully ef-
fective vaccine for some viruses, including PRRSV but
also viruses that cause extremely high mortality such as
ASFV. Induction of sterilizing immunity, i.e. complete
protection against a virus, remains the goal, yet in reality
no pig vaccine consistently induces sterilizing immunity
and a low level of virus replication after active infection
is not unexpected in vaccinated pigs. Interestingly, and
along these lines, a US research team reported earlier
this year on the development of an ASFV vaccine with
sterilizing immunity against the current Eurasia pan-
demic strain [128]. This group was able to achieve
complete attenuation of a highly virulent ASFV Georgia
strain by deleting a previously uncharacterized gene,
I177L [128]. We look forward to seeing how this prod-
uct performs in the field and perhaps using this as a
model for other pathogens.
Besides having a perfect/ideal vaccine against the tar-
get pathogen, important considerations for successful
vaccination are the number of doses required, the
vaccination route, and the correct timing as well as the
general ease of vaccine administration. In fact, it is cru-
cial in the early stages of vaccine development to clearly
define the target product profile (TPP) [129]. To define
the TPP, many things need to be considered including
the vaccine’s target market, the importance of the dis-
ease (economical losses), number of doses used,thermostability and others. Mixing of vaccine types such
as with heterologous prime boosting (for example one
dose of an inactivated vaccine followed by a booster dose
of an attenuated-live vaccine or a DNA vaccine) is gain-
ing momentum in pig production [87, 130] as it may be
possible to trigger a longer-lasting, broader immunity by
using two different vaccine types for the same pathogen
in the same pig.
In addition, novel viruses are discovered in pigs every
year and these may or may not be associated with dis-
ease. Better and faster assessment of the importance of
such viruses needs to take place. If a new virus or virus
variant causes financial losses in pig farms, a vaccine
needs to be available as soon as possible. This requires
the simultaneous use of all tools available for pathogen
assessment and subsequent vaccine design in several la-
boratories to attempt to reduce any possible losses for
pig producers. Vaccine research would likely benefit
from additional people working in the bioinformatics
area cooperating with and complementing the work of
traditional pathologists, virologists and immunologists.
Much has improved since mass-vaccinations entered
agriculture, but further improvements at the vaccination
stage, such as avoiding the transmission of pathogens via
vaccine equipment and reducing unnecessary stress to
pigs also need to be considered in future vaccine
developments.
Conclusion
In this review of the literature, we summarized current
information on traditional and novel methods to design,
produce and administer viral vaccines for use in pig pro-
duction. Although there has certainly been measurable
progress since veterinary vaccines were introduced ap-
proximately 150 years ago, attenuated-live and inacti-
vated vaccines are still most commonly used. With the
advent of affordable and fast gene sequencing, genomic
engineering, and bioinformatics we are likely soon to
realize major advances in the type and efficacy of
vaccines for pig producers with the opportunity to pick
and choose a vaccine that is tailored to specific
requirements.
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